Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 80% Improvement Relative Risk HCQ for COVID-19  Huang et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 1,255 patients in China Lower hospitalization with HCQ (p=0.001) c19hcq.org Huang et al., Annals of the Rheumatic .., Jun 2020 Favors HCQ Favors control

Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study

Huang et al., Annals of the Rheumatic Diseases 2020:79, 1163-1169, doi:10.1136/annrheumdis-2020-217425
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Analysis of 1255 COVID-19 patients in Wuhan Tongji Hospital finding 0.61% with systemic autoimmune diseases, much lower than authors expected (3%-10%). Authors hypothesise that protective factors, such as CQ/HCQ use, reduce hospitalization.
This study is excluded in the after exclusion results of meta analysis: significant unadjusted confounding possible.
risk of hospitalization, 80.0% lower, RR 0.20, p < 0.001, treatment 8, control 1,247.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huang et al., 16 Jun 2020, retrospective, China, peer-reviewed, 15 authors.
This PaperHCQAll
Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study
Yao Huang, Zhe Chen, Yu Wang, Liang Han, Kai Qin, Wenya Huang, Ying Huang, Hui Wang, Pan Shen, Xin Ba, Weiji Lin, Hui Dong, Mingmin Zhang, Professor Shenghao Tu
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217425
What is already known about this subject? ► On 12 March, WHO declared COVID-19 could be characterised as a pandemic. Till 22 April, more than 2.5 million cases of COVID-19 have been reported worldwide. ► Increasing data about COVID-19 based on the general population has been reported. However, little published works were found about COVID-19 in disease-specific groups. What does this study add? ► We analysed the epidemiology of 1255 inpatients with COVID-19 who were admitted to Wuhan Tongji Hospital. Additional 17 patients with systemic autoimmune diseases (AIDs) were further screened, the demographic characteristics, epidemiological history, comorbidities, clinical symptoms or signs on admission, chest CT findings, laboratory results on admission, therapies that were prescribed for COVID-19 as well as AIDs, and clinical outcomes were reported. The detailed information of patients with systemic AIDs was investigated.
Competing interests none declared. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research. Patient consent for publication not required. Ethics approval This study was approved by the ethics Commission of Tongji Hospital, Tongji Medical College, Huazhong University of science and Technology (TJ-iRB20200365). Written informed consent was waived by Tongji Hospital for emerging infectious diseases and the urgent need to collect data. Provenance and peer review not commissioned; externally peer reviewed. data availability statement Data are available upon reasonable request by email to shtu@ tjh. tjmu. edu. cn. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, on January 16, 2022 by guest. Protected by copyright. http://ard.bmj.com/
References
Chen N, Zhou, Dong, epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, doi:10.1016/S0140-6736(20)30211-7
Clinicaltrials, Gov, Post-exposure prophylaxis / preemptive therapy for saRs-Coronavirus-2-full text view
Gautret, Parola, Hydroxychloroquine and azithromycin as a treatment of COViD-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Guan, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Hari, Gs, Levy Ml, Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3), Nephron Clin Pract, doi:10.1001/jama.2016.0289
Hemminki, Huang, autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence, Semin Cancer Biol, doi:10.1016/j.semcancer.2019.06.005
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Jaillon S, Berthenet, Garlanda, sexual dimorphism in innate immunity, Clin Rev Allergy Immunol, doi:10.1007/s12016-017-8648-x
Kim Ahj, Sparks, Liew, a rush to judgment? rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COViD-19, Ann Intern Med, doi:10.7326/M20-1223
Li, Guan, Wu, early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, doi:10.1056/NEJMoa2001316
Lu, Zhao, Li, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, doi:10.1016/S0140-6736(20)30251-8
Roberts, Comparative United states autoimmune disease rates for 2010-2016 by sex, geographic region, and race, Autoimmun Rev, doi:10.1016/j.autrev.2019.102423
Smolen Js, Bijlsma, eUlaR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, Ann Rheum Dis, doi:10.1136/annrheumdis-2019-216655
Subramanian Vs, Ga, Tumor necrosis factor alpha reduces intestinal vitamin C uptake: a role for nF-κB-mediated signaling, Am J Physiol Gastrointest Liver Physiol, doi:10.1152/ajpgi.00071.2018
Wang, Me, Human autoimmune diseases: a comprehensive update, J Intern Med, doi:10.1111/joim.12395
Yao, Ye, Zhang, in vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (saRs-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COViD-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zhu N, Zhang, Wang, a novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
{ 'DOI': '10.1136/annrheumdis-2020-217425', 'ISSN': ['0003-4967', '1468-2060'], 'URL': 'http://dx.doi.org/10.1136/annrheumdis-2020-217425', 'abstract': '<jats:sec><jats:title>Objectives</jats:title><jats:p>Increasing data about COVID-19 have been ' 'acquired from the general population. We aim to further evaluate the clinical characteristics ' 'of COVID-19 in patients with systemic autoimmune diseases ' '(AIDs).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We included all ' 'confirmed inpatients with COVID-19 and systemic AIDs in Wuhan Tongji Hospital from 29 January ' 'to 8 March 2020. We retrospectively collected and analysed information on epidemiology of ' '1255 inpatients and additional clinical characteristics of patients with systemic AIDs. ' 'Outcomes were followed up until 16 April ' '2020.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of the 1255 ' 'patients with COVID-19, the median age was 64.0 years and 53.1% were male. More than half ' '(63.0%) had chronic comorbidities. The proportions of elderly, male and patients with ' 'comorbidities were significantly higher in intensive care unit (ICU) than in the general ward ' '(p&lt;0.001). 17 (0.61%) patients with systemic AIDs were further screened and analysed from ' '2804 inpatients. The median age was 64.0 years and 82.4% were female. All patients were ' 'living in Wuhan and two family clusters were found. 1 (5.9%) patient was admitted to ICU and ' 'one died. 10 (62.5%) of 16 patients changed or stopped their anti-AIDs treatments during ' 'hospitalisation, and 5 of them felt that the disease had worsened after the ' 'quarantine.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Older ' 'males with chronic comorbidities are more vulnerable to severe COVID-19. The lower proportion ' 'of COVID-19 in patients with systemic AIDs needs more high-quality human clinical trials and ' 'in-depth mechanism researches. Of note, the withdrawal of anti-AIDs treatments during ' 'hospitalisation can lead to flares of diseases.</jats:p></jats:sec>', 'alternative-id': ['10.1136/annrheumdis-2020-217425'], 'author': [ {'affiliation': [], 'family': 'Huang', 'given': 'Yao', 'sequence': 'first'}, {'affiliation': [], 'family': 'Chen', 'given': 'Zhe', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Wang', 'given': 'Yu', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Han', 'given': 'Liang', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-6180-7890', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Qin', 'given': 'Kai', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Huang', 'given': 'Wenya', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Huang', 'given': 'Ying', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-9651-2729', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Wang', 'given': 'Hui', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shen', 'given': 'Pan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ba', 'given': 'Xin', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Lin', 'given': 'Weiji', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Dong', 'given': 'Hui', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Zhang', 'given': 'Mingmin', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-8530-270X', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Tu', 'given': 'Shenghao', 'sequence': 'additional'}], 'container-title': 'Annals of the Rheumatic Diseases', 'container-title-short': 'Ann Rheum Dis', 'content-domain': {'crossmark-restriction': True, 'domain': ['bmj.com']}, 'created': {'date-parts': [[2020, 6, 16]], 'date-time': '2020-06-16T21:55:16Z', 'timestamp': 1592344516000}, 'deposited': { 'date-parts': [[2021, 5, 13]], 'date-time': '2021-05-13T06:25:06Z', 'timestamp': 1620887106000}, 'funder': [ { 'DOI': '10.13039/501100001809', 'award': ['81503426', '81573802', '81874383'], 'doi-asserted-by': 'publisher', 'name': 'National Natural Science Foundation of China'}], 'indexed': { 'date-parts': [[2023, 10, 10]], 'date-time': '2023-10-10T09:01:30Z', 'timestamp': 1696928490682}, 'is-referenced-by-count': 24, 'issue': '9', 'issued': {'date-parts': [[2020, 6, 16]]}, 'journal-issue': { 'issue': '9', 'published-online': {'date-parts': [[2020, 8, 14]]}, 'published-print': {'date-parts': [[2020, 9]]}}, 'language': 'en', 'license': [ { 'URL': 'https://bmj.com/coronavirus/usage', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 6, 16]], 'date-time': '2020-06-16T00:00:00Z', 'timestamp': 1592265600000}}], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-217425', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '239', 'original-title': [], 'page': '1163-1169', 'prefix': '10.1136', 'published': {'date-parts': [[2020, 6, 16]]}, 'published-online': {'date-parts': [[2020, 6, 16]]}, 'published-print': {'date-parts': [[2020, 9]]}, 'publisher': 'BMJ', 'reference': [ { 'DOI': '10.1056/NEJMoa2001017', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.1'}, { 'DOI': '10.1016/S0140-6736(20)30183-5', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.2'}, { 'DOI': '10.1016/S0140-6736(20)302518', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.3'}, { 'DOI': '10.1038/s41564-020-0695-z', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.4'}, { 'key': '2021051223200811000_79.9.1163.5', 'unstructured': 'WHO . World health organization, 2020.'}, { 'key': '2021051223200811000_79.9.1163.6', 'unstructured': 'National Health Commission . National health commission of the PRC, ' '2020.'}, { 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical characteristics of coronavirus disease 2019 in China', 'author': 'Guan', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'journal-title': 'N Engl J Med', 'key': '2021051223200811000_79.9.1163.7', 'volume': '382', 'year': '2020'}, { 'DOI': '10.1016/S0140-6736(20)30211-7', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.8'}, { 'DOI': '10.1056/NEJMoa2001316', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.9'}, { 'DOI': '10.1152/ajpgi.00071.2018', 'article-title': 'Tumor necrosis factor alpha reduces intestinal vitamin C uptake: a role ' 'for NF-κB-mediated signaling', 'author': 'Subramanian', 'doi-asserted-by': 'crossref', 'first-page': 'G241', 'journal-title': 'Am J Physiol Gastrointest Liver Physiol', 'key': '2021051223200811000_79.9.1163.10', 'volume': '315', 'year': '2018'}, { 'DOI': '10.1016/S0140-6736(20)30566-3', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.11'}, { 'DOI': '10.1159/000339789', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.12'}, { 'DOI': '10.1001/jama.2016.0289', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.13'}, { 'DOI': '10.1007/s12016-017-8648-x', 'article-title': 'Sexual dimorphism in innate immunity', 'author': 'Jaillon', 'doi-asserted-by': 'crossref', 'first-page': '308', 'journal-title': 'Clin Rev Allergy Immunol', 'key': '2021051223200811000_79.9.1163.14', 'volume': '56', 'year': '2019'}, { 'key': '2021051223200811000_79.9.1163.15', 'unstructured': 'Xinhua News Agency . Concentrating the whole hospital to save severe ' 'cases——dialogue with the president of Wuhan tongji hospital Wang ' 'Wei-Xinhua, 2020. Available: http://news.cn/'}, { 'DOI': '10.1016/j.autrev.2019.102423', 'article-title': 'Comparative United States autoimmune disease rates for 2010-2016 by ' 'sex, geographic region, and race', 'author': 'Roberts', 'doi-asserted-by': 'crossref', 'journal-title': 'Autoimmun Rev', 'key': '2021051223200811000_79.9.1163.16', 'volume': '19', 'year': '2020'}, { 'article-title': 'Autoimmune diseases and hematological malignancies: exploring the ' 'underlying mechanisms from epidemiological evidence', 'author': 'Hemminki', 'journal-title': 'Semin Cancer Biol', 'key': '2021051223200811000_79.9.1163.17', 'year': '2019'}, { 'DOI': '10.1111/joim.12395', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.18'}, { 'DOI': '10.1136/annrheumdis-2019-216655', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.19'}, { 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'author': 'Yao', 'doi-asserted-by': 'crossref', 'journal-title': 'Clin Infect Dis', 'key': '2021051223200811000_79.9.1163.20', 'year': '2020'}, { 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial', 'author': 'Gautret', 'doi-asserted-by': 'crossref', 'journal-title': 'Int J Antimicrob Agents', 'key': '2021051223200811000_79.9.1163.21', 'year': '2020'}, { 'DOI': '10.7326/M20-1223', 'doi-asserted-by': 'crossref', 'key': '2021051223200811000_79.9.1163.22', 'unstructured': 'Kim AHJ , Sparks JA , Liew JW , et al . A rush to judgment? rapid ' 'reporting and dissemination of results and its consequences regarding ' 'the use of hydroxychloroquine for COVID-19. Ann Intern Med ' '2020;03.doi:10.7326/M20-1223'}, { 'key': '2021051223200811000_79.9.1163.23', 'unstructured': 'Chinese Clinical Trial Register (ChiCTR) . The world health organization ' 'international clinical trials registered organization registered ' 'platform, 2020.'}, { 'key': '2021051223200811000_79.9.1163.24', 'unstructured': 'ClinicalTrials.gov . Post-exposure prophylaxis / preemptive therapy for ' 'SARS-Coronavirus-2- full text view, 2020. Available: ' 'https://clinicaltrials.gov/ct2/show/NCT04308668'}, { 'DOI': '10.1056/NEJM199101173240303', 'doi-asserted-by': 'publisher', 'key': '2021051223200811000_79.9.1163.25'}], 'reference-count': 25, 'references-count': 25, 'relation': {}, 'resource': {'primary': {'URL': 'https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-217425'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [ 'General Biochemistry, Genetics and Molecular Biology', 'Immunology', 'Immunology and Allergy', 'Rheumatology'], 'subtitle': [], 'title': 'Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a ' 'retrospective study', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'volume': '79'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit